Last Updated Sep 3, 2009 5:38 PM EDT
The document will doubtless be of interest to federal prosecutors, who in February sued Forest for allegedly promoting its anti-depressants for pediatric use without FDA approval, and paying kickbacks to doctors to encourage prescriptions. The complaint also alleges that the company hid a negative study that later was used by the FDA in a decision to give both drugs black box warnings.
The document also indicates that Forest expected to put Emory University on its payroll. About $100,000 was budgeted "for scientific discovery to support activity and programs related to junior faculty advancement," the document states:
(Emory has been a focus of undisclosed pharma funding before.)
And Forest wanted 2,000 doctors on its payroll, the Times notes:
Under "Rep Promotional Programs," the document said the company planned to spend $34.7 million to pay 2,000 psychiatrists and primary care doctors to deliver 15,000 marketing lectures to their peers in one year.That comes out to about $17,350 each.
AstraZeneca, Merck, Wyeth and GlaxoSmithKline have all been accused of funding ghostwriting this year.
- See BNET's previous coverage of Lexapro:
- JAMA Demands Silence From Those Who Find Conflicts Among Its Authors
- Forest Labs' Lexapro Flap Over JAMA Article Will Likely Be Examined by the Feds
- Suit vs. Forest Labs Names Execs Linked to Alleged Lies About Lexapro, Celexa
- See BNET's previous coverage of ghostwriting:
- Inside GSK's CASSPER Ghostwriting Program
- "CASSPER" Was GSK's Friendly Ghostwriting Program on Paxil
- Allergan Gets on the GSK Merry-Go-Round for a Second Time
- Docs Say Merck Placed Their Names on Ghostwritten Vioxx Articles
- Elsevier Accused Again in Ghostwriting Scandal - This Time in Wyeth Prempro/Premarin Cases
- Wyeth's Troubles: Ghostwriting to Be Revealed; Centrum Sales Weak
- AstraZeneca's "Smoke and Mirrors" Man Has New Job in Medical Writing
- AZ Seroquel Trial: Was It "Ghostwriting" or "Professional" Writing?